Temozolomide in patients with high grade gliomas

Alba Ariela Brandes, Lara Maria Pasetto, Francesca Vastola, Silvio Monfardini

Research output: Contribution to journalArticle


The incidence of central nervous system neoplasias ranges from 3.8 to 5.1 cases per 100,000 inhabitants. First-line treatment of brain tumors consists of surgery associated with radiotherapy, and followed or not by chemotherapy. When used as an adjuvant therapy after surgery and radiotherapy, chemotherapy prolongs the time to progression and the median survival time. At relapse, chemotherapy is the common therapeutic approach. In recent years, new drugs for the treatment of brain tumors have been tested, and some of them, such as temozolomide, are very promising. Copyright (C) 2000 S. Karger AG, Basel.

Original languageEnglish
Pages (from-to)181-186
Number of pages6
Issue number3
Publication statusPublished - 2000


  • Brain tumors
  • Chemotherapy
  • Temozolomide

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Temozolomide in patients with high grade gliomas'. Together they form a unique fingerprint.

  • Cite this

    Brandes, A. A., Pasetto, L. M., Vastola, F., & Monfardini, S. (2000). Temozolomide in patients with high grade gliomas. Oncology, 59(3), 181-186.